Navigation Links
AFRESA(R) Phase 3 Pulmonary Function Safety Data in Patients with Diabetes Presented at ADA
Date:6/6/2009

Two-year study presented at the American Diabetes Association's 69th Scientific Sessions shows investigational product comparable to standard insulin therapy in pulmonary function tests

NEW ORLEANS, June 6 /PRNewswire-FirstCall/ -- AFRESA(R) (insulin human [rDNA origin]) Inhalation Powder is a well-tolerated, ultra rapid acting insulin with changes in pulmonary function tests comparable to usual antidiabetic treatment, according to data presented today at the American Diabetes Association's 69th Scientific Sessions. Results from the prospective, multicenter, phase 3 study conducted over a two-year period showed no difference in mean change in forced expiratory volume in one second (FEV(1)) between those treated with AFRESA and those treated with standard insulin therapy.

"Current mealtime insulin therapies, while accepted as an effective means to control glucose levels, have several limitations," said Peter Richardson, Corporate Vice President and Chief Scientific Officer, MannKind Corporation. "Our encouraging findings indicate that AFRESA may be a promising new treatment option with less weight gain and lower risk of hypoglycemia compared with current mealtime insulin therapy."

AFRESA is a novel, ultra rapid acting mealtime insulin therapy with an action profile that mimics meal-related early insulin release. Based on an extensive phase 3 clinical program, a New Drug Application (NDA) has been accepted by the U.S. Food and Drug Administration (FDA) requesting approval to market AFRESA Inhalation Powder and the AFRESA Inhaler for use in adult patients with type 1 and type 2 diabetes mellitus for the treatment of hyperglycemia. AFRESA is conveniently administered by oral inhalation.

Diabetes, which affects 23.6 million people in the U.S., or 8 percent of the population, is characterized by the body's inability to properly regulate levels of blood glucose, or blood sugar. Insulin, a hormone
'/>"/>

SOURCE MannKind Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Peregrine Pharmaceuticals Highlights Promising Early Data From Its Three Phase II Bavituximab Cancer Trials
2. PARI Pharma Reports Successful Phase Ib Clinical Results for Inhaled Liposomal Cyclosporine A and Gains FDA Orphan Drug Designation for the Prevention and Treatment of Bronchiolitis Obliterans
3. Medivation Announces Positive New Efficacy Data From Phase 1-2 Trial of MDV3100 in Advanced Prostate Cancer Patients
4. Arena Pharmaceuticals Announces the Presentation of Lorcaserin Phase 3 BLOOM Data at the American Diabetes Associations 69th Scientific Sessions
5. PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryxs Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference
6. Neurobiological Technologies Partner, Celtic Pharma, Announces Results of XERECEPT(R) Phase 3 Clinical Program
7. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
8. Trubion Announces Positive Data From a Phase 1 / 2 Study of TRU-016 for the Treatment of Chronic Lymphocytic Leukemia (CLL)
9. Entremed Presents Results of ENMD-2076 Phase 1 Study in Advanced Cancer Patients
10. TNFerade(TM) Phase III Data Presented at ASCO
11. Ironwood and Forest Present Additional Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... , July 24, 2014   AcelRx Pharmaceuticals, ... company focused on the development and commercialization of innovative ... today confirmed the PDUFA date for Zalviso remains July ... a rumor circulated online stating the Food and Drug ... 2014 there has been no notification to the company ...
(Date:7/24/2014)... Germany , and MARSEILLE, France ... , Exclusive global license from University of ... including next-generation sequencing (NGS) gene panels, for blood cancers  ... by new test, indicate favorable prognosis for patients with ... QIAGEN sees potential for developing companion diagnostics to guide ...
(Date:7/24/2014)... 24, 2014 Amgen (NASDAQ: AMGN ) ... results on Tuesday, July 29, 2014, after the close of ... a conference call with the investment community at 2 p.m. ... Robert A. Bradway , chairman and chief executive officer, and ... audio of the conference call will be simultaneously broadcast over ...
Breaking Medicine Technology:AcelRx Pharmaceuticals Confirms July 27, 2014 PDUFA Date for Zalviso 2QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 2QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 3QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 4QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 5Amgen Announces Webcast of 2014 Second Quarter Financial Results 2
... CAESAREA, Israel, March 23, 2011 EndyMed ... use of multi-source radiofrequency for professional aesthetic treatments, announced ... on 3DEEP radiofrequency technology, "A novel method ... treatments". This article was published ...
... CLEVELAND, March 23, 2011 DATATRAK International, Inc. ... on global eClinical solutions for the clinical trials ... Information Association,s EuroMeeting. The 23rd Annual EuroMeeting will ... while evaluating the benefits new science and technologies ...
Cached Medicine Technology:EndyMed Medical's Novel Multi-Source Radiofrequency Device Enables Real Time Skin Impedance Measurements 2EndyMed Medical's Novel Multi-Source Radiofrequency Device Enables Real Time Skin Impedance Measurements 3DATATRAK to Attend DIA's 23rd Annual EuroMeeting 2
(Date:7/25/2014)... 25, 2014 Yisrayl Hawkins, Pastor and Overseer ... on his blog explaining why so many prayers are going ... , In the article, Yisrayl gives many examples around ... the results. For example, in one case, in the small ... grounds to pray for rain; ironically, they received a massive ...
(Date:7/25/2014)... July 25, 2014 iTanSmart is a ... iPads. The app provides a tailored approach to eliminating ... dangerous sunburns and skin damage. In his review, Eaton ... and capabilities of iTanSmart. , Eaton begins his ... as a ‘better organized’ and ‘great alternative’ to its ...
(Date:7/25/2014)... According to the Liver Cirrhosis ... Vkool.com, this is a comprehensive guide that provides ... safe remedies for liver cirrhosis . This ...     Chapter 1: Liver Cirrhosis Bible & ... About Liver Basics ,     Chapter 3: Getting ...
(Date:7/25/2014)... DC (PRWEB) July 25, 2014 At ... Washington DC July 19, 17 participating developmentally-disabled teens and ... fun, even if off-road bicycling, canoeing and hiking can ... national non-profit at the scenic Chesapeake and Ohio ... of participating athletes both disabled and able-bodied. Under slightly ...
(Date:7/24/2014)... 2014 Dr. Henry H. Ting, a ... has been appointed senior vice president and chief quality ... his new role, he will oversee the hospital's clinical ... successfully led quality initiatives and interprofessional teams at the ... for the Door-to-Balloon Alliance, a collaboration of more than ...
Breaking Medicine News(10 mins):Health News:Yisrayl Hawkins Says Prayers for Rain Result in Violent Hail Because Prayers Are Not Being Heard in New Post 2Health News:Yisrayl Hawkins Says Prayers for Rain Result in Violent Hail Because Prayers Are Not Being Heard in New Post 3Health News:iTanSmart® Suntan App by UV Technologies, LLC Gets a ‘Big Thumbs Up’ from New York Times App Smart Columnist, Kit Eaton 2Health News:iTanSmart® Suntan App by UV Technologies, LLC Gets a ‘Big Thumbs Up’ from New York Times App Smart Columnist, Kit Eaton 3Health News:Liver Cirrhosis Bible & Ezra Protocol Review Exposes Debra Elkin's Liver Cirrhosis Treatment Guide – Vkool - Better Information, Better Lives 2Health News:Liver Cirrhosis Bible & Ezra Protocol Review Exposes Debra Elkin's Liver Cirrhosis Treatment Guide – Vkool - Better Information, Better Lives 3Health News:DC Adventure Team Challenge Thrills Developmentally-Disabled Participants 2Health News:DC Adventure Team Challenge Thrills Developmentally-Disabled Participants 3Health News:NewYork-Presbyterian Hospital Names New Senior Vice President for Quality and Patient Safety 2Health News:NewYork-Presbyterian Hospital Names New Senior Vice President for Quality and Patient Safety 3
... Record Revenue and Earnings per Share for the ... leading,provider of clinical software, connectivity and information solutions ... for the three,months and year ended December 31, ... revenue for the three months ended December 31, ...
... wife,of Red Sox star Dustin Pedroia, recently joined the ... be speaking out about the,dangers of tanning. She should ... a,year after her last dance at her senior prom ... http://www.newscom.com/cgi-bin/prnh/20080213/DC14158 ), "I really had no idea ...
... Leadership ... Team, Safeguards, METAIRIE, La., ... and dental practices,worldwide, today lauded the Securities and Exchange Commission,s (SEC) ... of OCA, Inc. (OCA). In conjunction with the filing of the,complaint, ...
... 13, 2008 -- The first genome-wide search for genes ... social creatures -- the amoebae Dictyostelium discoideum -- have ... behavior. , The study by scientists at Rice University ... this week by the journal Nature. It marks one ...
... ATLANTA, Feb. 13 Vendormate, Inc. announced ... America (CHCA) to make,Vendormate VISION(TM), its vendor ... children,s hospitals. Vendormate VISION(TM) is,used by leading ... better manage,the increasingly complex requirements of government-mandated ...
... Feb. 13 Quintiles,Transnational Corp. today announced that ... the College of American Pathologists (CAP)., The ... in the first,quarter of 2007. The facility has ... analytical capabilities to a growing test menu., ...
Cached Medicine News:Health News:Allscripts Reports Fourth Quarter 2007 Results 2Health News:Allscripts Reports Fourth Quarter 2007 Results 3Health News:Allscripts Reports Fourth Quarter 2007 Results 4Health News:Allscripts Reports Fourth Quarter 2007 Results 5Health News:Allscripts Reports Fourth Quarter 2007 Results 6Health News:Allscripts Reports Fourth Quarter 2007 Results 7Health News:Allscripts Reports Fourth Quarter 2007 Results 8Health News:Allscripts Reports Fourth Quarter 2007 Results 9Health News:Allscripts Reports Fourth Quarter 2007 Results 10Health News:Kelli Pedroia, Wife of Red Sox Dustin Pedroia, Joins Melanoma Foundation of New England to Warn About Tanning for the Prom 2Health News:OrthoSynetics(TM) Applauds SEC Suit Against Former Company Management 2Health News:Microbial 'cheaters' help scientists ID 'social' genes 2Health News:Microbial 'cheaters' help scientists ID 'social' genes 3Health News:Vendormate and CHCA Finalize Agreement to Offer Compliance and Security Solutions to Children's Hospitals 2Health News:Quintiles Central Laboratory in India Receives CAP Certification 2
Gillies (Converse) Skin Hook, small hook size....
The Accuref 8001 allows you to measure much smaller pupils than conventional units and 3 step Target light adjuster ensures accurate results....
Sterile free isotonic balanced salt solution...
Sterile Silicone Oil for Intraocular Application....
Medicine Products: